

Breast Cancer HER-2 Positive

A study of patients with HER2-positive breast cancer (APHINITY)

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT01358877 2010-022902-41
(EudraCT number) BO25126

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

F. Hoffmann-La Roche Ltd
Sponsor

Phase III
Phase

NCT01358877 2010-022902-41 (EudraCT number) BO25126
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 years and older

Healthy Volunteers
No